Femoral-popliteal Arteriosclerosis Obliterans:Review of Evidence-based Studies on Drug-eluting Endovascular Treatment.
10.3881/j.issn.1000-503X.10849
- Author:
Rui ZHANG
1
;
Zhi Chao LAI
1
;
Chang Wei LIU
1
Author Information
1. Department of Vascular Surgery,PUMC Hospital,CAMS and PUMC,Beijing 100730,China.
- Publication Type:Journal Article
- MeSH:
Angioplasty, Balloon;
Arteriosclerosis Obliterans;
therapy;
Drug-Eluting Stents;
trends;
Humans;
Popliteal Artery;
pathology;
Stents;
Treatment Outcome
- From:
Acta Academiae Medicinae Sinicae
2019;41(2):256-260
- CountryChina
- Language:Chinese
-
Abstract:
Atherosclerosis-related diseases have increasingly become health concerns with the increased living conditions and aging.Globally,about 200 million people have suffered from arteriosclerosis obliterans(ASO),which can even be life-threatening in some cases.The past seven decades have witnessed the rapid advances in the treatment of ASO,which has developed from surgery to endovascular interventions including plain balloon angioplasty,bare metal stent placement,drug-coated balloon,and drug-eluting stent.However,the roles of these new techniques for femoral-popliteal lesions,especially their real-world clinical outcomes and indications,remain unclear.This article reviews the latest evidences on the use of drug-eluting devices in treating femoral-popliteal arteriosclerosis obliterans.
